QuVa Pharma Achieves National Agreement with Premier for Outsourced Compounded Preparations

QuVa Pharma Achieves Landmark Agreement with Premier, Inc.

QuVa Pharma, Inc., a leading provider of outsourced sterile injectable compounding services, has announced that it has been awarded a significant national group purchasing agreement with Premier, Inc. This new agreement, effective November 1, 2025, allows Premier members the opportunity to benefit from pre-negotiated pricing and terms for outsourced compounded preparations.

CEO and Co-Founder, Stuart Hinchen, emphasized the long-standing relationship with Premier, stating, "We are proud to have served Premier's members for over six years and are excited to be awarded a new agreement." This milestone reflects QuVa's commitment to enhancing collaboration with healthcare providers and ensuring they have reliable access to a diverse range of quality sterile injectables that are essential for patient care.

The Importance of QuVa's Offerings

QuVa's facilities, which comply with cGMP and are FDA registered as 503B outsourcing centers, play a critical role in supporting health system operations and hospital pharmacies. This agreement is not just about pricing; it underpins QuVa’s capacity to help hospitals meet their operational needs while minimizing compliance risks. Their offerings include a vast product portfolio, robust capacity utilization across multiple automated production facilities, comprehensive warehousing, and distribution capabilities complemented by transparent customer service and a safety-first orientation.

Premier operates as a powerful healthcare improvement company that joins approximately 4,350 hospitals with 325,000 other providers and organizations. By utilizing integrated data analytics, collaborative efforts, supply chain solutions, and consulting services, Premier works towards delivering better care outcomes efficiently while reducing costs. The partnership with QuVa further enhances Premier’s ability to transform healthcare experiences.

Innovative Solutions from QuVa

In addition to compounding services, QuVa also provides innovative software solutions designed to empower health-system pharmacies. Their flagship product, Quva BrightStream, utilizes AI-powered machine learning and predictive analytics. This software aggregates and normalizes fragmented health-system data, facilitating the analysis of large volumes of complex health information across various care sites. The actionable insights derived from this data enable pharmacy operations to optimize workflows, reduce expenses, manage inventory effectively, and deal with drug shortages efficiently. QuVa's model allows pharmacies to maximize their value from contracts and ensure comprehensive formulary management.

The dedication to excellence and responsible management in pharmacy operations underscores QuVa's mission to not only meet but also exceed the quality standards in patient care. Through this new agreement with Premier, QuVa is positioning itself as an essential partner in the evolution of healthcare.

As health systems continue to navigate complexities within the industry, QuVa's integration of compounding services and advanced software solutions remains crucial. Their commitment towards delivering top-tier medical supplies, strengthened by their operational excellence and innovative technology, exemplifies a significant forward leap in pharmacy management practices.

Overall, the agreement reflects QuVa's ongoing dedication to enhancing healthcare quality, accessibility, and operational efficiency for its partners and patients. As the collaboration deepens, the potential for improved healthcare delivery looks exceptionally promising. This agreement not only reinforces QuVa’s robust position in the market but also signals a pivotal shift towards smarter, integrated healthcare solutions for providers across the nation.